Ganoderma lucidum ethanol extract inhibits the inflammatory response by suppressing the NF-κB and toll-like receptor pathways in lipopolysaccharide-stimulated BV2 microglial cellsC

Experimental and Therapeutic Medicine

Volumn 5, Issue 3, 2013, Pages 957-963

  Yoon, Hyun Min ^a   Jang, Kyung Jun ^a   Han, Min Seok ^a   Jeong, Jin Woo ^a,b   Kim, Gi Young ^c   Lee, Jai Heon ^d   Choi, Yung Hyun ^a,b  

^a Dong Eui University   (South Korea)

^b Dong Eui University   (South Korea)

^c Jeju National University   (South Korea)

^d Dong A University   (South Korea)

Author keywords

BV2 microglia; Ganoderma lucidum; Inflammation; Nuclear factor B; Toll like receptor

Indexed keywords

ACTIN; GANODERMA LUCIDUM EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NUCLEOLIN; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MICROGLIA; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84873103293     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.895     Document Type: Article

References (50)

1. Mahajna J, Dotan N, Zaidman BZ, Petrova RD and Wasser SP: Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutr Cancer 61: 16-26, 2009.
2. Boh B, Berovic M, Zhang J and Zhi-Bin L: Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13: 265-301, 2007.
3. Paterson RR: Ganoderma-a therapeutic fungal biofactory. Phytochemistry 67: 1985-2001, 2006.
4. Yuen JW and Gohel MD: Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 53: 11-17, 2005.
5. + NK-cell cytotoxicity in cord blood. Bioorg Med Chem 12: 5603-5609, 2004.
6. Hu H, Ahn NS, Yang X, Lee YS and Kang KS: Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 102: 250-253, 2002.
7. Lin SB, Li CH, Lee SS and Kan LS: Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 72: 2381-2390, 2003.
8. Hong KJ, Dunn DM, Shen CL and Pence BC: Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res18: 768-770, 2004.
9. Stanley G, Harvey K, Slivova V, Jiang J and Sliva D: Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-β1 from prostate cancer cells. Biochem Biophys Res Commun 330: 46-52, 2005.
10. Müller CI, Kumagai T, O'Kelly J, Seeram NP, Heber D and Koeffler HP: Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res 30: 841-848, 2006.
11. Jang KJ, Han MH, Lee BH, Kim BW, Kim CH, Yoon HM and ChoiYH: Induction of apoptosis by ethanol extracts of Ganoderma lucidum in human gastric carcinoma cells. J Acupunct Meridian Stud 3: 24-31, 2010.
12. Cheung WM, Hui WS, Chu PW, Chiu SW and Ip NY: Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett 486: 291-296, 2000.
13. Zhao HB, Lin SQ, Liu JH and Lin ZB: Polysaccharide extract isolated from Ganoderma lucidum protects rat cerebral cortical neurons from hypoxia/reoxygenation injury. J Pharmacol Sci 95: 294-298, 2004.
14. Lai CS, Yu MS, Yuen WH, So KF, Zee SY and Chang RC: Antagonizing beta-amyloid peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum. Brain Res 1190: 215-224, 2008.
15. Zhou ZY, Tang YP, Xiang J, Wua P, Jin HM, Wang Z, Mori M and Cai DF: Neuroprotective effects of water-soluble Ganoderma lucidum polysaccharides on cerebral ischemic injury in rats. J Ethnopharmacol 131: 154-164, 2010.
16. Perry VH and Gordon S: Macrophages and microglia in the nervous system. Trends Neurosci 92: 273-274, 1998.
17. Sawada M, Kondo N, Suzumura A and Marunouchi T: Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 491: 394-397, 1989.
18. Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D and Rossi F: Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 373: 647-650, 1995.
19. Dandona P, Ghanim H, Chaudhuri A, Dhindsa S and Kim SS: Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp Mol Med 42: 245-253, 2010.
20. Gonzalez-Scarano F and Baltuch G: Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22: 219-240, 1999.
21. Amor S, Puentes F, Baker D and van der Valk P: Inflammation in neurodegenerative diseases. Immunology 129: 154-169, 2010.
22. Dheen ST, Kaur C and Ling EA: Microglial activation and its implications in the brain diseases. Curr Med Chem 14: 1189-1197, 2007.
23. Eikelenboom P and van Gool WA: Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 111: 281-294, 2004.
24. Gao HM, Liu B, Zhang W and Hong JS: Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24: 395-401, 2003.
25. Liu B and Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1-7, 2003.
26. Bae DS, Kim YH, Pan CH, Nho CW, Samdan J, Yansan J and Lee JK: Protopine reduces the inflammatory activity of lipopolysaccharide-stimulated murine macrophages. BMB Rep45: 108-113, 2012.
27. Jin CY, Moon DO, Lee KJ, Kim MO, Lee JD, Choi YH, Park YM and Kim GY: Piceatannol attenuates lipopolysaccharide-induced NF-kappaB activation and NF-kappaB-related proinflammatory mediators in BV2 microglia. Pharmacol Res 54: 461-467, 2006.
28. Lee JW, Lee MS, Kim TH, Lee HJ, Hong SS, Noh YH, HwangBY, Ro JS and Hong JT: Inhibitory effect of inflexinol on nitric oxide generation and iNOS expression via inhibition of NF-κB activation. Mediators Inflamm 2007: 93148-93157, 2007.
29. Baima ET, Guzova JA, Mathialagan S, Nagiec EE, Hardy MM, Song LR, Bonar SL, Weinberg RA, Selness SR, WoodardSS, Chrencik J, Hood WF, Schindler JF, Kishore N and MbalavieleG: Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-κB essential modulator binding domain peptides. J Biol Chem 285: 13498-13506, 2010.
30. Miller SI, Ernst RK and Bader MW: LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 3: 36-46, 2005.
31. Lee YH, Jeon SH, Kim SH, Kim C, Lee SJ, Koh D, Lim Y, Ha K and Shin SY: A new synthetic chalcone derivative, 2-hydroxy-3',5,5'-trimethoxychalcone (DK-139), suppresses the Toll-like receptor 4-mediated inflammatory response through inhibition of the Akt/NF-κB pathway in BV2 microglial cells. Exp Mol Med 44: 369-377, 2012.
32. Romanovsky AA, Steiner AA and Matsumura K: Cells that trigger fever. Cell Cycle 5: 2195-2197, 2006.
33. Fukuzawa M, Yamaguchi R, Hide I, Chen Z, Hirai Y, SugimotoA, Yasuhara T and Nakata Y: Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull 31: 1933-1937, 2008.
34. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB and Bisen PS: Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol 10: 717-742, 2009.
35. Xu Z, Chen X, Zhong Z, Chen L and Wang Y: Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med 39: 15-27, 2011.
36. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-BaileyD, Croxtall J and Willoughby DA: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91: 2046-2050, 1994.
37. Hawkey CJ: Cox-2 inhibitors. Lancet 353: 307-314, 1999.
38. Giovannini MG, Scali C, Prosperi C, Bellucci A, Pepeu G and Casamenti G: Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 16: 31-40, 2003.
39. MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Ann Rev Immunol 15: 323-330, 1997.
40. Mitchell JA, Larkin S and Williams TJ: Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol50: 1535-1542, 1995.
41. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y and HirschEC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172: 151-154, 1994.
42. Murphy S: Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 29: 1-13, 2000.
43. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G and Probert L: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153: 801-813, 1998.
44. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI and O'Callaghan JP: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16: 1474-1476, 2002.
45. Rothwell N, Allan S and Toulmond S: The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J Clin Invest 100: 2648-2652, 1997.
46. Baldwin AS Jr: The NF-kappaB and I-kappaB proteins: new discoveries and insights. Ann Rev Immunol 14: 649-683, 1996.
47. Moon DO, Choi YH, Kim ND, Park YM and Kim GY: Anti-inflammatory effects of β-lapachone in lipopolysaccharidestimulated BV2 microglia. Int Immunopharmacol 7: 506-514, 2007.
48. Trinchieri G and Sher A: Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7: 179-190, 2007.
49. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
50. Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, Akira S, KishimotoT, Nakanishi K and Fujimoto J: Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology 41: 443-450, 2005.